Paloma Shemirani, 23, died at Royal Sussex County Hospital on July 24 2024, after declining the treatment for non-Hodgkin ...

COVID-19 vaccination boosters protect people with cancer developing from severe COVID-19, according to a study published ...

Pemivibart was well tolerated and prophylactic against COVID-19 infection among adult patients with significant immunocompromising conditions.

Theresa Gaffney is the lead Morning Rounds writer and reports on health care, new research, and public policy, with a ...

Key Points - GAAP revenue reached $0.85 million in Q2 2025, exceeding analyst estimates and Revenue more than doubled compared to Q2 2024, also exceeding analyst estimates. GAAP loss per share ...

TytoCare, a leading Israeli telemedicine company based in Netanya, is willing to work with Vietnamese regulators, insurers, ...

Childhood cancer survivors have a higher risk of developing severe COVID-19 than the general population, according to research published in The Lancet Regional Health: Europe.

Cash Position: GeoVax reported cash balances of $3,093,862 at June 30, 2025, as compared to $5,506,941 at December 31, 2024. During July 2025, the Company completed a public offering of common stock ...

The analysis found that chemotherapy and prior thrombotic events increase the risk for COVID-related hospitalization, while ...

By pairing an mRNA-style vaccine with traditional cancer immunotherapy drugs known as immune checkpoint inhibitors, they were ...

Many people have recently questioned the relevance of the COVID vaccine. However new study shows that it has a positive ...

As the latest wave of COVID-19 shows no signs of abating, University of South Australia experts say it's not just booster ...